BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 19567591)

  • 1. Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.
    Nishida T; Hudecek M; Kostic A; Bleakley M; Warren EH; Maloney D; Storb R; Riddell SR
    Clin Cancer Res; 2009 Jul; 15(14):4759-68. PubMed ID: 19567591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revealing tumor immunity after hematopoietic stem cell transplantation.
    Wu CJ; Ritz J
    Clin Cancer Res; 2009 Jul; 15(14):4515-7. PubMed ID: 19584145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
    Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
    Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
    Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
    Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-myeloablative transplants for malignant disease.
    Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
    Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissection and molecular analysis of alloreactive CD8+ T cell responses in allogeneic haematopoietic stem cell transplantation.
    Wölfel C; Lennerz V; Lindemann E; Hess G; Derigs HG; Huber C; Herr W; Wölfel T
    Cancer Immunol Immunother; 2008 Jun; 57(6):849-57. PubMed ID: 18004563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal analyses of leukemia-associated antigen-specific CD8
    Rücker-Braun E; Link CS; Schmiedgen M; Tunger A; Vizjak P; Teipel R; Wehner R; Kühn D; Fuchs YF; Oelschlägel U; Germeroth L; Schmitz M; Bornhäuser M; Schetelig J; Heidenreich F
    Exp Hematol; 2016 Nov; 44(11):1024-1033.e1. PubMed ID: 27473564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of 4 novel HLA-B*40:01 restricted minor histocompatibility antigens and their potential as targets for graft-versus-leukemia reactivity.
    Griffioen M; Honders MW; van der Meijden ED; van Luxemburg-Heijs SA; Lurvink EG; Kester MG; van Bergen CA; Falkenburg JH
    Haematologica; 2012 Aug; 97(8):1196-204. PubMed ID: 22419570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.
    Brudno JN; Somerville RP; Shi V; Rose JJ; Halverson DC; Fowler DH; Gea-Banacloche JC; Pavletic SZ; Hickstein DD; Lu TL; Feldman SA; Iwamoto AT; Kurlander R; Maric I; Goy A; Hansen BG; Wilder JS; Blacklock-Schuver B; Hakim FT; Rosenberg SA; Gress RE; Kochenderfer JN
    J Clin Oncol; 2016 Apr; 34(10):1112-21. PubMed ID: 26811520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells.
    Zorn E; Wang KS; Hochberg EP; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Clin Cancer Res; 2002 Jul; 8(7):2052-60. PubMed ID: 12114403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of B-cell chronic lymphocytic leukemia (B-CLL)-reactive T-cell lines and clones from HLA class I-matched donors using modified B-CLL cells as stimulators: implications for adoptive immunotherapy.
    Hoogendoorn M; Wolbers JO; Smit WM; Schaafsma MR; Barge RM; Willemze R; Falkenburg JH
    Leukemia; 2004 Jul; 18(7):1278-87. PubMed ID: 15116118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation.
    Kollgaard T; Petersen SL; Hadrup SR; Masmas TN; Seremet T; Andersen MH; Madsen HO; Vindeløv L; thor Straten P
    Leukemia; 2005 Dec; 19(12):2273-80. PubMed ID: 16304575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.
    Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P
    J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome.
    Khouri IF; Bassett R; Poindexter N; O'Brien S; Bueso-Ramos CE; Hsu Y; Ferrajoli A; Keating MJ; Champlin R; Fernandez-Vina M
    Cancer; 2011 Oct; 117(20):4679-88. PubMed ID: 21455998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II.
    van Balen P; van Bergen CAM; van Luxemburg-Heijs SAP; de Klerk W; van Egmond EHM; Veld SAJ; Halkes CJM; Zwaginga JJ; Griffioen M; Jedema I; Falkenburg JHF
    Front Immunol; 2018; 9():3016. PubMed ID: 30619360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
    Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
    J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia.
    Gladstone DE; Fuchs E
    Curr Opin Oncol; 2012 Mar; 24(2):176-81. PubMed ID: 22234253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic MHC gene transfer enhances antitumor activity of allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease.
    Ohashi M; Kobayashi A; Hara H; Miura Y; Yoshida K; Kushida M; Ikarashi Y; Mandai M; Kitajima M; Yoshida T; Aoki K
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2208-15. PubMed ID: 16609036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation.
    Riddell SR; Berger C; Murata M; Randolph S; Warren EH
    Blood Rev; 2003 Sep; 17(3):153-62. PubMed ID: 12818225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.